Since 2015, IVF success rates have stagnated, with current embryo selection methods offering limited improvement. Over 40% of negative outcomes stem from transferring embryos with low viability. Traditional techniques are slow, costly, and often ineffective, leading to multiple IVF cycles, increased miscarriages, and 25% higher treatment costs for patients.
Conceptom Ltd enables IVF clinics to improve live birth rates through non-invasive, AI-powered embryo viability assessment. Their technology identifies non-viable embryos with 90% predictive accuracy, reducing miscarriages by 2x and increasing successful pregnancies by up to 1.4x. Clinics can reduce the number of IVF cycles per patient by 30%, improving patient outcomes and lowering costs.
Pilots: Clinical validation & ESHRE presentation (2024)
Maturity: Pre-commercial
Capital raised: 200K€
Valuation: 5.5M€
Open Round: Yes
Conceptom’s plug-and-play Raman spectrometer collects spectral data from spent culture media in 3 minutes per embryo. AI-based models instantly analyze viability without requiring transportation or lab processing. Clinics access the platform via an annual subscription and pay-per-test model. The patented technology is scalable and backed by a team with deep expertise in embryology, AI, and medical devices.
Sector: Health Tech
Country: Portugal
Team: 3
